Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Metformin-Glibenclamide Combination Is More Effective Than Monotherapy In Type 2 Diabetes

        A DGReview of :"Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance(R)) in type 2 diabetes"
        Diabetes, Obesity & Metabolism

        04/24/2003
        By James Adams


        A single-tablet combination of metformin and glibenclamide is more effective at lowering blood glucose than is monotherapy with either drug.

        Antihyperglycaemic effects of the combination therapy are greatest in patients with haemoglobin A1c (HbA1c) equal to or above 8% at baseline, according to investigators, but its advantage over either monotherapy is irrespective of baseline HbA1c, age or body mass index.

        The investigators, from multiple international institutions including Baylor College of Medicine and The Methodist Hospital in Houston, Texas, United States, and Hôpital Bichat in Paris, France, studied 1,856 patients from 3 randomised, double-blind, multi-centre, parallel-group clinical trials. Patients were stratified at baseline by HbA1c levels, age and body mass index, and the efficacy of the study treatments were evaluated for each subgroup.

        Results showed that the combination therapy was more effective than either monotherapy irrespective of baseline HbA1c, age or body mass index. Patients with baseline HbA1c at 8% or higher experienced the greatest antihyperglycaemic effects with all treatments, but especially with the combination therapy.

        Age and body mass index had no effect on the efficacy of the metformin-glibenclamide combination.

        Hypoglycaemic symptoms were greatest in patients who had baseline HbA1c lower than 8%. Hypoglycaemic symptoms did not increase with age.

        The investigators conclude that the combination therapy has a greater blood glucose lowering efficacy than monotherapy. It is well tolerated in patients with hyperglycaemia that has been inadequately controlled by diet and exercise.
        Diabetes Obes Metab 2003;5:3:171-179. "Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance(R)) in type 2 diabetes"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send